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Microsomal epoxide hydrolase (mEH) plays a dual role in the detoxification and activation of tobacco procarcinogens. Two
polymorphisms affecting enzyme activity have been described in the exons 3 and 4 of the mEH gene, which result in the substitution
of amino acids histidine to tyrosine at residue 113, and arginine to histidine at residue 139, respectively. We performed a hospital-
based case–control study consisting of 277 newly diagnosed lung cancer patients and 496 control subjects to investigate a possible
association between these two polymorphisms and lung cancer risk. The polymorphisms were determined by polymerase chain
reaction/restriction fragment length polymorphism and TaqMan assay using DNA from peripheral white blood cells. Logistic
regression was performed to calculate odds ratios (ORs), confidence limits (CL) and to control for possible confounders. The exon 3
polymorphism of the mEH gene was associated with a significantly decreased risk of lung cancer. The adjusted OR, calculated relative
to subjects with the Tyr113/Tyr113 wild type, for the His113/His113 genotype was 0.38 (95% CL 0.20–0.75). An analysis according
to histological subtypes revealed a statistically significant association for adenocarcinomas; the adjusted OR for the His113/His113
genotype was 0.40 (95% CL 0.17–0.94). In contrast, no relationship between the exon 4 polymorphism and lung cancer risk was
found. The adjusted OR, calculated relative to the His139/His139 wild type, was for the Arg139/Arg139 genotype 1.83 (0.76–4.44).
Our results support the hypothesis that genetically reduced mEH activity may be protective against lung cancer.
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It is estimated that smoking is responsible for about 90% of lung
cancer cases. Since not all smokers develop lung cancer, it has been
hypothesised that polymorphisms in genes encoding enzymes
involved in the metabolisms of tobacco carcinogens such as the
microsomal epoxide hydrolase (mEH) may influence an indivi-
dual’s susceptibility to lung cancer.
Microsomal epoxide hydrolase, a phase II metabolic enzyme,
catalyses the hydrolysis of arene, alkene and aliphatic epoxides
from polycyclic aromatic hydrocarbons and aromatic amines.
Although this hydrolysis is generally a detoxification reaction
because less reactive and more watersoluble trans-dihydrodiols are
produced (Oesch, 1973), in the case of some hydrocarbons such as
benzo(a)pyrene, present in tobacco smoke, more highly reactive
and mutagenic compounds for example the 7,8-diol-9,10 epoxide
are generated in the metabolic process (Sims et al, 1974). Thus,
mEH exhibits a dual role of procarcinogen detoxification and
activation (Shou et al, 1996) and may be considered a cancer risk
factor as well as a protective factor, depending on the carcinogens.
The gene for human mEH, consisting of nine exons, has been
mapped with in situ hybridisation to chromosome 1q42.1 (1p11-
qter) (Hartsfield et al, 1998). In the coding region of the mEH gene,
two relatively common genetic polymorphisms are characterised
within exons 3 and 4. (Hassett et al, 1994a, b). In exon 3 of the
mEH gene, a C has been substituted for a T, resulting in a tyrosine
replacement by histidine at codon 113. In vitro expression analyses
indicate that this amino-acid change results in a 40–50% decrease
in enzyme activity and thus the allele has been called the ‘slow
allele’. The second polymorphism occurs in exon 4, a G to A
transition, causing a histidine to arginine change at codon 139.
This polymorphism has been referred to as the ‘fast allele’ as this
change results in a 25% increase of enzyme activity (Hassett et al,
1994a).
We conducted a hospital-based case–control study of 277
patients with primary lung cancer and 496 controls without a
history of cancer, all of them Austrian Caucasians, to investigate
whether the mEH polymorphisms in exons 3 and 4 are associated
with lung cancer risk.
MATERIAL AND METHODS
Study population
Lung cancer cases were recruited consecutively since January 1997
from the Pulmological Center, Baumgartner Hoehe, Vienna,
Austria’s largest hospital for the treatment of pulmonary diseases. Received 27 March 2003; revised 8 May 2003; accepted 14 May 2003
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histologically confirmed lung cancer patients.
Histological data were available for 255 cases, of those 27.1%
had squamous cell carcinoma, 51.0% adenocarcinoma, 4.7%
large-cell carcinoma, 14.5% small-cell carcinoma, 0.7% alveolar-
cylinder-cell carcinoma and 2.0% mixed histological subtypes.
Patients were derived from the Surgical Department (34%)
and the Department of Internal Medicine (66%). The hospital-
based control group (n¼496) was recruited at the same time
period from the Departments of Urology (41.0%), Orthopedics
(15.6%), Gynaecology (11.9%) and Head and Neck (1.9%) of
the University Hospital of Vienna; the Department of Internal
Medicine (16.8%) and the Department of Surgery (0.8%) of the
Pulmological Center; the Department of Urology (1.5%) of
the ‘Kaiser Franz Josef Hospital’, an outpatient clinic (8.9%) and
relatives of the students involved in this study (1.5%). Only
individuals without a history of cancer were eligible for participa-
tion as controls. The human subjects protocol for this study was
reviewed and approved by the institutional review boards of the
participating hospitals. Written informed consent was obtained
from all the included subjects.
Genotyping analyses
Heparinised peripheral blood mononuclear cells (PBMCs) were
isolated by Ficoll–Paque gradient centrifugation (Amersham
Pharmacia Biotech, Arlington Heights, IL, USA). Genomic DNA
was extracted from PBMC, using QIAamp Blood Kit (Quiagen
GmbH, Germany).
The mEH polymorphisms in exons 3 and 4 were determined
by two separate polymerase chain reaction (PCR)-based methods
using primers as described by Harrison et al (1999). Briefly,
the amplification reactions were carried out in a 50ml volume
consisting of 200ng genomic DNA, 0.2mM of each primer (VBC-
Genomics, Vienna, Austria), 0.2mM deoxynuclotide triphosphate
(Roche, Vienna, Austria), 1.5mM MgCl2,5 ml1 0   PCR Buffer II
(Applied Biosystems, Norwalk, CT, USA) and 1U AmpliTaq DNA
Polymerase (Applied Biosystems). Polymerase chain reactions
were performed with a thermocycler 2400 from Applied Biosys-
tems with the following conditions: 941C for 5min, followed by 35
cycles of 951C for 30s, annealing temperature of 551C (exon 3) or
621C (exon 4) for 30s and 721C for 30s, with a final extension of
721C for 7min.
A1 0 ml aliquot of the appropriate PCR product was digested
with 10U of the restriction enzyme EcoRV (exon 3) and RsaI
(exon 4) (New England Biolabs, Hitchin, UK) at 371C for
4h and separated on a 3% ethidium bromide-stained agarose
gel.
The allelic discrimination of the mEH exon 3 polymorphism was
reassessed with the ABI PRISM 7000 Sequence Detection Systems
(Applied Biosystems), using the fluorogenic 50nuclease assay with
TaqMan Minor Groove Binder (MGB) probes. The wild-type
TaqMan MGB probe was FAM labelled (50-TCAACAGATACCCT-
CAC-30) and the mutant probe was VIC labelled (50-TCAACAGA-
CACCCTC-30). The final volume for each reaction was 25ml,
consisting of 12.5ml TaqMan Universal PCR Master Mix (Applied
Biosystems), 0.6mM of each primer (forward primer 50-CTGGAA-
GAAGCAGGTGGAGATT-30 and reverse primer 50-TCTGGCTGG-
CGTTTTGC-30), 0.2mM of each TaqMan probe and 100ng genomic
DNA. The PCR profile was an initial denaturation step at 951C for
10min and 40 cycles with 951C for 15s and 601C for 1min,
fluorescent signals were measured at 601C.
Genotyping was done blinded to case–control status. For quality
control, 20% of the samples were randomly repeated; no
discrepancies were observed.
Statistical analyses
Univariate statistical analyses included descriptive statistics
for age, sex, pack-years, mEH3 and mEH4. Multiple logistic
regressions were performed to calculate odds ratios (ORs) and
confidence limits (CL) and to adjust for confounders. Confounders
included were age, sex and pack-years of cigarettes smoked.
Smoking habits were coded as neversmokers and quartiles of pack-
years smoked (see Table 2). Deviation of the genotypes from a
Hardy–Weinberg equilibrium was assessed using w
2 statistics. The
final multiple logistic regression model was: log(P(cancer)/(1 P
(cancer))¼b0þageþsexþpack-year_quartilesþmEH3þmEH4.
To evaluate different histological subtypes, squamous cell carci-
nomas, adenocarcinomas and small-cell carcinomas were sepa-
rately analysed using multiple logistic regression and including the
same confounders as above. All P-values are two-sided; P-values
o0.05 were considered to be statistically significant. Analysis of
the data was performed using the computer software SPSS for
Windows (version 10.0).
RESULTS
In Table 1 selected characteristics of the study population, which
consisted of 277 lung cancer patients and 496 controls, are
presented. There were no statistically significant differences
between the cases and controls in age, mean age was 64 years in
the cases and 63 years in the controls. The percentage of males was
68.2% for cases and 67.7% for controls. The means of pack-years
for cigarettes smoked showed differences between cases (52.8) and
controls (33.5). Furthermore, ORs for lung cancer with respect to
quartiles of pack-years are shown in Table 2; a highly significant
dose–response relationship was found.
The gene frequencies for controls were not in Hardy–Weinberg
equilibrium for the exon 3 polymorphism (Po0.0001) using the
conventional polymerase chain reaction/restriction fragment
length polymorphism (PCR/RFLP) genotyping, whereas using a
fluorogenic 50nuclease TaqMan assay they were found to be in
Hardy–Weinberg equilibrium (P¼0.93). The deviation from
Hardy–Weinberg equilibrium was attributable to genotyping
Table 1 Principal patient characteristics in the study population (n¼773)
Pack-years Age (years)
Study population Gender Mean (s.d.) Mean (s.d.)
Cases (n¼277) Female (n¼88) 44.5 (23.1) 64 (12)
Male (n¼189) 55.7 (28.6) 64 (11)
Total (n¼277) 52.8 (27.6) 64 (11)
Controls (n¼496) Female (n¼160) 22.1 (16.4) 62 (13)
Male (n¼336) 36.6 (28.5) 63 (12)
Total (n¼496) 33.5 (27.0) 63 (12)
All n¼773 42.3 (28.9) 63 (12)
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19 (54.29%) of the heterozygote patients falsely classified as His113
homozygotes (data not shown). For the statistical analysis,
only results performed by the TaqMan assay were used for the
exon 3 polymorphism (Table 3). There was a statistically
significant difference in the distribution of genotypes between
cases and controls for the exon 3 polymorphism of mEH.
The prevalence of the His113/His113 genotype was significantly
lower (P¼0.014) in the lung cancer cases (5.8%) than in
the controls (10.9%). The adjusted OR, calculated relative
to subjects with the Tyr113/Tyr113 wild type, was 0.38 (95%
CL 0.20–0.75). The heterozygous Tyr113/His113 genotype was also
lower in the cancer group (41.2%) compared to the control group
(43.9%), although the difference was not statistically significant
(P¼0.77).
Table 4 shows the mEH exon 4 genotype distribution for cases
and controls. The gene frequencies for controls were found to be in
Hardy–Weinberg equilibrium for the exon 4 polymorphism
(P¼0.905). The adjusted OR, calculated relative to the His139/
His139 wild type, was 1.01 (95% CL 0.69–1.47) for the His139/
Arg139 genotype and 1.83 (0.76–4.44) for the Arg139/Arg139
genotype, respectively.
An analysis according to histological types and the mEH exon 3
polymorphism was performed, where a statistically significant
association for adenocarcinoma was found (Table 5). The adjusted
OR, calculated relative to the mEH exon 3 wild type, for the
His113/His113 genotype was 0.40 (95% CL 0.17–0.94). Other
histological subtypes such as squamous cell carcinoma and small-
cell carcinoma revealed no statistically significant association (data
not shown).
Table 2 Distribution of quartiles of pack-years of smoked cigarettes in cases and controls and adjusted
ORs
a
Pack-years (quartiles) Cases (n¼277) Controls (n¼496) OR (95% CL) P
0 31 (11.2%) 202 (40.7%) 1
0.1–22.0 26 (9.4%) 113 (22.8%) 1.97 (1.08–3.57) 0.03
22.0–38.5 51 (18.4%) 83 (16.7%) 5.52 (3.18–9.57) 0.00
38.5–57.7 84 (30.3%) 48 (9.7%) 17.91 (10.01–32.03) 0.00
57.7–288.0 85 (30.7%) 50 (10.1%) 18.07 (10.10–32.34) 0.00
aAdjusted for age, gender, mEH4 and mEH3.
Table 3 Distribution of the mEH3 polymorphism in cases and controls and adjusted OR
a
Genotype Total (n¼773) Cases (n¼277) Controls (n¼496) OR (95% CL)
a P
Wild type 371 147 (53.0%) 224 (45.2%) 1
Tyr113/Tyr113
Heterozygous 332 114 (41.2%) 218 (43.9%) 0.77 (0.54–1.09) 0.77
Tyr113/His113
Homozygous 70 16 (5.8%) 54 (10.9%) 0.38 (0.20–0.75) 0.014
His113/His113
aAdjusted by age, gender, smoking status (pack-years) and mEH4.
Table 4 Distribution of the mEH4 polymorphism in cases and controls and adjusted OR
a
Genotype Total (n¼773) Cases (n¼277) Controls (n¼496) OR (95% CL)
a P
Wildtype
His139/His139 552 186 (67.1%) 336 (67.7%) 1
Heterozygous
His139/Arg139 224 80 (28.9%) 144 (29.0%) 1.01 (0.69–1.47) 0.95
Homozygous
Arg139/Arg139 27 11 (4.0%) 16 (3.2%) 1.83 (0.76–4.44) 0.18
aAdjusted for age, gender, smoking status (pack-years) and mEH3.
Table 5 Distribution of the mEH3 polymorphism in adenocarcinomas and controls and adjusted ORs
a
Genotype Total (n¼622) Adenocarcinomas (n¼126) Controls (n¼496) OR (95% CL)
a P
Wildtype 296 72 (57.1%) 224 (45.2%) 1
Tyr113/Tyr113
Heterozygous 264 46 (36.5%) 218 (43.9%) 0.63 (0.40–1.00) 0.048
Tyr113/His113
Homozygous 62 8 (6.4%) 54 (10.9%) 0.40 (0.17–0.94) 0.035
His113/His113
aAdjusted for age, gender, smoking status (pack-years) and mEH4.
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sDISCUSSION
In this hospital-based case–control study of Austrian Caucasians,
we investigated the association between mEH genetic polymorph-
ism and the risk of lung cancer. Our results suggest that the variant
genotype of the mEH exon 3 polymorphism is a protective
factor for lung cancer, whereas the exon 4 polymorphism of mEH
has no influence on lung cancer risk. Using the conventional PCR/
RFLP genotyping with primers designed by Harrison et al (1999),
the alleles for the polymorphism in exon 3 were not in Hardy–
Weinberg equilibrium, whereas the alleles of exon 4 polymorphism
were found to be in Hardy–Weinberg equilibrium, arguing against
a selection bias. This finding is in accordance with other studies
using primers designed by Harrison et al (1999) for the genotyping
of the exon 3 polymorphism. In their Caucasian control
population, Zhou et al (2001) found genes such as the NADPH
quinone oxidoreductase, N-acetyltransferase-2 and mEH exon 4
polymorphism in Hardy–Weinberg equilibrium, but not the
exon 3 polymorphism. As this finding suggests a misclassification
bias, they retested a random of their samples (5%) using different
primers and restriction enzymes. However, they found no
discordant results, evidently due to the low percentage of
their repeats. They conclude that the deviation from Hardy–
Weinberg equilibrium of the exon 3 polymorphism requires
further studies.
The reverse primer of Harrison et al abuts directly at the
mutation site and an engineered base change produces an EcoRV
restriction enzyme site in the wild type. Within this reverse primer,
aG -A polymorphism at codon 119 is contained (Yoshikawa et al,
2000), which may affect the accuracy of the exon 3 genotyping.
Baxter et al (2002) found that this primer mismatch in Tyr113/
His113 heterozygotes leads to a false His113/His113 genotype when
the codon 119 A allele is present. Hence, we reassessed the allelic
discrimination of the mEH exon 3 polymorphism with a
fluorogenic 50nuclease assay using TaqMan Minor Groove Binder
(MGB) probes. Indeed we found 57.53% of the heterozygote
controls and 54.29% of the heterozygote patients falsely classified
as homozygotes. In the statistical analysis, only results performed
by the TaqMan assay were included.
The variant alleles His113 and Arg139 of the mEH polymorph-
isms were relatively common, allele frequencies in controls were
0.33 and 0.18, respectively. These frequencies of our control
population were comparable to those of previous studies
conducted in Caucasian populations, where the frequency of the
rare His113 allele ranged from 0.28 to 0.40; of the Arg139 allele
from 0.15 to 0.18 (Benhamou et al, 1998; London et al, 2000; To-
Figueras et al, 2001).
One of the first studies investigating the association between
lung cancer risk and mEH genotypes was conducted by Benhamou
et al (1998), who found a significant dose–response relationship
between predicted enzyme activity and lung cancer risk in French
Caucasian smokers. Consecutively, a number of case–control
studies have examined the influence of the mEH polymorphisms
on lung cancer risk (Persson et al, 1999; Lin et al, 2000; London
et al, 2000; To-Figueras et al, 2001; Wu et al, 2001; Zhao et al, 2002;
Zhou et al, 2001, 2002), resulting in somewhat inconsistent
findings. Recently, Lee et al (2002) performed a meta-analysis of
seven published studies and a pooled analysis of four published
and four unpublished studies to investigate the association of the
mEH polymorphisms and lung cancer risk. The results of the
meta-analysis indicate no statistically significant association
between the two mEH polymorphisms and lung cancer risk.
However, in the pooled analysis, comprised of 986 cases and 1633
controls, a significant decrease in lung cancer risk was observed
for the exon 3 polymorphic homozygous genotype with an OR of
0.70 (95% confidence interval (CI)¼0.51–0.96), adjusted for age,
sex, smoking and centre. In contrast, no effect for the exon 4
polymorphism was detectable.
An analysis according to the main histological subtypes, namely
adenocarcinoma, squamous cell carcinoma and small-cell carci-
noma, revealed a statistically significant association for adenocar-
cinoma, whereas no significant association was found neither
for squamous cell carcinoma nor small-cell carcinoma. This
finding is in accordance with the meta-analysis by Lee et al
(2002), who found the protective effect of the mEH exon 3
polymorphism stronger for adenocarcinoma than for other
histological types.
In conclusion, the results of this Austrian Caucasian study
support the hypothesis that genetically reduced mEH activity may
be protective against lung cancer, especially for adenocarcinoma,
as we found a statistically significant reduced risk for individuals
homozygous for the exon 3 variant allele. Therefore, the genetic
polymorphism at exon 3 of the mEH gene represents a possible
mechanism for the modulation of carcinogen disposition that may
influence individual susceptibility to cancer development.
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